Carboplatin is a platinum-based cross-linking agent that exhibits immunomodulatory and anticancer chemotherapeutic activities. Carboplatin binds DNA with slower kinetics than other platinum drugs, inhibiting DNA transcription and replication; it is clinically used to treat various cancers. Carboplatin also modulates STAT signaling and release of HMGB-1.
| Cas No. | 41575-94-4 |
|---|---|
| Purity | ≥98% |
| Formula | C6H12N2O4Pt |
| Formula Wt. | 371.25 |
| Chemical Name | (SP-4-2)-Diammine-[1,1-cyclobutanedi(carboxylato- κO)(2-)]platinum |
| IUPAC Name | azane;cyclobutane-1,1-dicarboxylate;platinum(2+) |
| Synonym | Paraplati; cis-Diammine[1,1 cyclobutane dicarboxylato] platinum |
| Melting Point | 228-230°C |
| Solubility | Soluble in water. |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | C0171 MSDS PDF |
|---|---|
| Info Sheet | C0171 Info Sheet PDF |
| Brochures | JAK/STAT Flyer |
Hato SV, Khong A, de Vries IJ, et al. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014 Jun 1;20(11):2831-7. PMID: 24879823.
Chen X, Wu Y, Dong H, et al. Platinum-based agents for individualized cancer treatment. Curr Mol Med. 2013 Dec;13(10):1603-12. PMID: 24206132.
Ang WH, Myint M, Lippard SJ. Transcription inhibition by platinum-DNA cross-links in live mammalian cells. J Am Chem Soc. 2010 Jun 2;132(21):7429-35. PMID: 20443565.
